OK, so it’s a “baker’s three” (8) today. Makes up for yesterday’s zero…!
Patent-holder urges FDA to NOT approve prasugrel (from Lilly/Daiichi Sankyo).
Novartis getting cold feet at the Alcon altar? – Novartis betrothed itself to Alcon, but it may not follow through with the engagement. CEO Daniel Vasella told Bloomberg that his company might just pass on its option to buy a majority stake in the eye-care company…more
Abbott and AstraZeneca apply for combo drug approval – CERTRIAD is an investigational compound containing the active ingredients of CRESTOR and TRILIPIX under development by Abbott and AstraZeneca for the treatment of mixed dyslipidemia…more
Hope for treating resistant TB? – An experimental drug that starves the bacteria responsible for tuberculosis makes conventional therapy five times more effective against drug-resistant TB, doctors reported on Wednesday. The company-run study found that the Johnson & Johnson drug TMC207, if added to a standard cocktail of five other TB medicines, cleared traces of the tuberculosis bacteria in the sputum of 48 percent of the volunteers after eight weeks. Only 9 percent of patients given the five older drugs alone showed that type of improvement…more
Genzyme buys up rights to Campath from Bayer (for potential MS treatment)
Takeda‘s nex-gen diabetes drug (alogliptin) delayed in Europe also. Major blow.
Questions swirling around Roche/Genentech‘s Avastin – Cancer researchers are beginning to ask why Roche‘s very expensive and very lucrative drug Avastin is not providing bigger survival gains for cancer patients… “Is it a home run drug? No,” says Jennifer Litton, a breast cancer specialist at M.D. Anderson Cancer Center. “When I’ve seen it work, it works phenomenally, but we need to get smarter as to who those people are that get those dramatic responses.”…more
PLUS – what is J&J up to? Here’s the preview…
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff